Fragile X Syndrome Day: Clinical Challenges, Care Strategies, and Emerging Therapies
Share
Subscribe
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In episode 171, “Fragile X Syndrome Day: Clinical Challenges, Care Strategies, and Emerging Therapies,” Craig A. Erickson, MD, professor of psychiatry at Cincinnati Children’s Hospital, discussed the evolving landscape of Fragile X syndrome (FXS) care in honor of National Fragile X Syndrome Day. Erickson reviewed current challenges in recognizing and diagnosing FXS. He also underscored the importance of genetic testing and outlined key counseling points for families once a diagnosis is confirmed.
Erickson, who also serves as the director of the Cincinnati Fragile X Research and Treatment Center, provided an overview of behavioral and neuropsychiatric management across the lifespan. He highlighted evidence-informed approaches for ADHD, irritability and aggression, and anxiety, as well as the critical role of early intervention and structured supports in adulthood. The discussion closed with a look at emerging therapeutics and how these advances may reshape clinical practice and long-term outcomes for individuals with FXS.
Looking for more Genetic Disorders discussion? Check out the NeurologyLive® Genetic Disorders clinical focus page.
Episode Breakdown:
- 1:25 – Challenges in recognizing and diagnosing Fragile X
- 3:25 – Genetic counseling and cascade testing after diagnosis
- 6:00 – Managing behavioral and neuropsychiatric symptoms
- 9:55 – News Minute
- 12:45 – Clinical management across the lifespan
- 17:12 – Emerging therapies and research priorities
- 21:17 – Why Fragile X awareness remains critical
The stories featured in this week’s Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
- FDA Accepts NDA for Apnimed’s AD109 for the Treatment of Obstructive Sleep Apnea
- FDA Accepts NDA for Axsome Therapeutics’ AXS-12 for the Treatment of Cataplexy in Narcolepsy
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.